Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS phase 3 trial of subcutaneous efgartigimod PH20 in adults with pemphigus
MOH_2020-12-20_009583Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Dec 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) comparing Efgartigimod PH20 + prednisone with Placebo + prednisone (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2020; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on MOH_2020-12-20_009583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-20_009583.